SIDE AGREEMENT to the License Agreement dated 1st July 2016 between UCB Biopharma Sprl and Syndax Pharmaceuticals, Inc. (“License Agreement”)Side Agreement • May 9th, 2017 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
This side agreement (this “Agreement”) is entered into as of the latest date of signature appearing below by and between UCB Biopharma Sprl, a Belgian corporation with offices located at Allée de la Recherche 60, 1070 Brussels, Belgium (“UCB”) and Syndax Pharmaceuticals, Inc. a Delaware corporation with offices located at 35 Gatehouse Drive, Building D, Floor 3, Waltham, Massachusetts 02451, USA (“Company”). UCB and Company are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
AMENDMENT #2 TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • May 9th, 2017 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment #2 to LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (“Amendment”), is entered into between Syndax Pharmaceuticals, Inc., a Delaware corporation having a place of business at 400 Totten Pond Road, Suite 110, Waltham, MA 02451 USA (“Syndax”) and Kyowa Hakko Kirin Co., Ltd., a Japanese corporation having a place of business at 1-9-2, Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan (“KHK”), effective as of January 16, 2017 (the “Amendment Effective Date”).
AMENDMENT NO. 8 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRIN CANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC.Trial Agreement • May 9th, 2017 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 8 to Clinical Trial Agreement (the “Amendment” or “Amendment 8”) is entered into as of January 18, 2017 (the “Effective Date”), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals, Inc. (“Company” or “Syndax”).
AMENDMENT NO. 7 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRIN CANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC.Trial Agreement • May 9th, 2017 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 7 to Clinical Trial Agreement (the “Amendment” or “Amendment 7”) is entered into as of January 9, 2017 (the “Effective Date”), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals, Inc. (“Company” or “Syndax”).
